J Burgos-Burgos1, V Vega1, D Macias-Verde1, V Gómez1,2, M Travieso-Aja1, J Travieso1, E Vicente1, C Santana1, J Ospina1,2, P C Lara3,4. 1. Breast Cancer Unit, Centro Oncológico Integral Canario (COIC), Hospital Universitario San Roque, Dolores de la Rocha 5, 35001, Las Palmas, GC, Spain. 2. Universidad Fernando Pessoa Canarias. Dolores de La Rocha 14, 35001, Las Palmas, GC, Spain. 3. Breast Cancer Unit, Centro Oncológico Integral Canario (COIC), Hospital Universitario San Roque, Dolores de la Rocha 5, 35001, Las Palmas, GC, Spain. plara@ufpcanarias.es. 4. Universidad Fernando Pessoa Canarias. Dolores de La Rocha 14, 35001, Las Palmas, GC, Spain. plara@ufpcanarias.es.
Abstract
INTRODUCTION: Hypofractionated whole breast irradiation (HWBI) is the current standard of treatment after breast conservative surgery (BCS). Intraoperative radiotherapy (IORT) must be associated to WBI in patients showing high-risk factors of local recurrence in the definitive pathology report. The aim of this trial was to evaluate, for the first time, the acute toxicity and cosmesis of HWBI after photon-IORT. MATERIALS AND METHODS: Twenty-six luminal breast cancer patients treated by BCS and IORT(20 Gy) were included between February and December 2019, in this prospective trial, of adjuvant HWBI (40.5 Gy/2.67 Gy/15 fractions). Acute toxicity (CTCAEv5.0) and cosmesis (Harvard scale), were assessed 3 months after treatment. RESULTS: All patients completed their treatment without interruptions. All cases were evaluable 3 months after treatment showing no toxicity ≥ G3 and excellent/good cosmesis assessment in 88% of the patients. CONCLUSION: HWBI seems to have similar acute toxicity and cosmesis results than conventionally fractionated WBI in combination to photon-IORT after BCS.
INTRODUCTION: Hypofractionated whole breast irradiation (HWBI) is the current standard of treatment after breast conservative surgery (BCS). Intraoperative radiotherapy (IORT) must be associated to WBI in patients showing high-risk factors of local recurrence in the definitive pathology report. The aim of this trial was to evaluate, for the first time, the acute toxicity and cosmesis of HWBI after photon-IORT. MATERIALS AND METHODS: Twenty-six luminal breast cancerpatients treated by BCS and IORT(20 Gy) were included between February and December 2019, in this prospective trial, of adjuvant HWBI (40.5 Gy/2.67 Gy/15 fractions). Acute toxicity (CTCAEv5.0) and cosmesis (Harvard scale), were assessed 3 months after treatment. RESULTS: All patients completed their treatment without interruptions. All cases were evaluable 3 months after treatment showing no toxicity ≥ G3 and excellent/good cosmesis assessment in 88% of the patients. CONCLUSION: HWBI seems to have similar acute toxicity and cosmesis results than conventionally fractionated WBI in combination to photon-IORT after BCS.
Entities:
Keywords:
Boost; Breast cancer; Hypofractionated radiotherapy; IORT
Authors: Matthias Pez; Anke Keller; Grit Welzel; Yasser Abo-Madyan; Michael Ehmann; Benjamin Tuschy; Sebastian Berlit; Marc Sütterlin; Frederik Wenz; Frank A Giordano; Elena Sperk Journal: Strahlenther Onkol Date: 2019-10-22 Impact factor: 3.621
Authors: David Krug; René Baumann; Stephanie E Combs; Marciana Nona Duma; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Marc D Piroth; Felix Sedlmayer; Rainer Souchon; Vratislav Strnad; Wilfried Budach Journal: Strahlenther Onkol Date: 2021-01-28 Impact factor: 3.621